Recombinant Cyclin E1 Antibody - Primary antibody, specific to Cyclin E1

Cat. No.: Ab098460

GRAU & PUREZA Recombinant, ExactAb™, Validated, See COA

Application

IF/ICC, WB

Host species

Rabbit

Reactive species

Human

Isotype

Rabbit IgG

Conjugation

Unconjugated

Visão geral

Rabbit anti Human Cyclin E1 Antibody, Recombinant, could be used for WB, IF/ICC and so on.

Especificações

Product Name

Recombinant Cyclin E1 Antibody - Primary antibody, specific to Cyclin E1

Sinónimos

CCNE antibody | Ccne1 antibody | CCNE1_HUMAN antibody | cyclin E variant ex5del antibody | cyclin E variant ex7del antibody | Cyclin E1 antibody | Cyclin Es antibody | Cyclin Et antibody | CyclinE antibody | G1/S specific cyclin E antibody | G1/S-specific

Especificações e pureza

Recombinant, ExactAb™, Validated, See COA

Mecanismos bioquímicos e fisiológicos

Essential for the control of the cell cycle at the G1/S (start) transition. Post-translational: Phosphorylation of Thr-395 by GSK3 and of Ser-399 by CDK2 accelerates degradation via the ubiquitin proteasome pathway. Phosphorylated upon DNA damage, probabl

Espécie hospedeira

Rabbit

Especificidade

Cyclin E1

Imunogénio

A synthetic peptide derived from human Cyclin E1 (AA 350-410).

Controlo positivo

WB: HeLa, Jurkat, Hep-G2, MCF-7, SH-SY5Y lysates. IF/ICC: HeLa cells.

Conjugação

Unconjugated

Grau

ExactAb™, Recombinant, Validated

Tipo de corrente de luz

kappa

SDS-PAGE

150 kDa

Método de purificação

Protein A purified

Concentração

See COA

Nota

Replacement Part Number Ab098463

Product Line

Produtos biológicos

Armazenamento e envio

Forma

Liquid

Condições de armazenamento de armazenamento

Store at -20°C,Avoid repeated freezing and thawing

Enviado em

Ice chest + Ice pads

Estabilidade e armazenamento

Store at 2-8℃ short term (1-2 weeks). Store at -20℃ long term (24 months). Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Imagens

Western Blot: Recombinant Cyclin E1 Antibody (Ab098460)

Recombinant Cyclin E1 Antibody (Ab098460) - Western Blot
All lanes: Recombinant Cyclin E1 Antibody (Ab098460) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 47 kDa
Observed band size: 45 kDa
Exposure time: 40.0 s

IF/ICC: Recombinant Cyclin E1 Antibody (Ab098460)

Recombinant Cyclin E1 Antibody (Ab098460) - IF/ICC
Immunofluorescent analysis of HeLa cells, using Recombinant Cyclin E1 Antibody (Ab098460).

Aplicação

Aplicação

Dilution info

IF/ICC

1/50-1/200

WB

1/1000 - 1/2000

Alvos associados (humanos)

CCNE1 Tchem G1/S-specific cyclin-E1 (0 Activities)

Discover Target: CCNE1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application Protocols

• Tested/validated applications: Not specified for this item; refer to CoA/Spec Sheet.
• Recommended dilutions and incubation conditions: Not specified for this item; refer to CoA/Spec Sheet.
• Positive/negative controls: Not specified for this item; refer to CoA/Spec Sheet.

General suggestion (literature/general): When establishing protocols for Cyclin E1 detection, include synchronized cell lysates (G1/S) as positive controls and CCNE1 knockout/siRNA lysates as negative controls. Perform titration curves to determine optimal working dilutions for your assay.

Biological Roles

• Target overview (literature/general)

  • Cyclin E1 (gene CCNE1) is a regulatory cyclin that forms an active kinase complex with CDK2 to drive the G1 to S phase transition. Cyclin E1 accumulates in late G1, promoting phosphorylation of substrates involved in DNA replication initiation and centrosome duplication.

• Mechanistic context

  • Cyclin E1–CDK2 activity triggers RB pathway inactivation via phosphorylation, releasing E2F transcription factors that upregulate S-phase genes. Cyclin E1 is regulated by transcriptional control, proteasomal degradation (SCF–Fbw7-mediated ubiquitination), and inhibitory binding proteins.
  • Dysregulated Cyclin E1 levels are associated (in research contexts) with altered proliferation and genome stability; researchers frequently monitor Cyclin E1 as a cell-cycle biomarker.

• Experimental implications

  • Expression is cell-cycle dependent: synchronization strategies (double-thymidine, aphidicolin, or hydroxyurea blocks) enrich for Cyclin E1 for detection.
  • Post-translational modifications (e.g., phosphorylation) and proteolytic processing can alter epitope exposure; antibody selection and assay design should consider whether epitopes are conformation- or PTM-sensitive.
  • Subcellular localization: Predominantly nuclear during late G1/early S; fixation/permeabilization conditions influence detection in IF/ICC.

• Species orthology (general)

  • Cyclin E1 is conserved across vertebrates; cross-reactivity is clone/epitope-dependent and must be verified empirically. Species reactivity for this specific item is not specified; consult CoA/Spec Sheet.

Buffer Applications

• Item-specific formulation details: Not specified for this item; refer to CoA/Spec Sheet.

• General guidance for antibody buffers (literature/general)

  • Storage/dilution buffers: PBS or TBS at pH ~7.2–7.6 with 0.02–0.05% sodium azide (if compatible with downstream assays) and optional 10–50% glycerol for freeze–thaw protection. For functional assays with live cells or azide-sensitive enzymes, use azide-free buffers.
  • Blocking agents: 1–5% BSA, nonfat dry milk, or serum can reduce nonspecific binding; choose based on detection system (milk can interfere with phospho-specific detection due to casein).
  • Detergents: 0.05–0.1% Tween-20 in wash buffers (TBS-T/PBS-T) to minimize background.
  • Antigen retrieval (IHC): Heat-induced retrieval in citrate (pH ~6) or Tris-EDTA (pH ~9) buffers may enhance Cyclin E1 epitope exposure; optimize empirically.
  • IP buffers: Maintain physiological salt (150 mM NaCl), mild nonionic detergents (0.1–1% NP-40/Triton X-100), and protease/phosphatase inhibitors as needed.

All compositions above are general best practices and not specifications for this item.

Green Alternatives

Although “green alternatives” usually pertain to organic solvents, sustainability also applies to antibody sourcing and use.

• Ethical and environmental considerations (literature/general)

  • Recombinant vs animal-derived: Recombinant production reduces reliance on animal immunization/ascites generation, lowering ethical and biowaste concerns.
  • Lot consistency: Higher reproducibility reduces repeat experiments and reagent waste, improving overall environmental footprint.
  • Preservative choices: Azide-free or low-toxicity preservatives may be preferred for cell-based work and wastewater impact, where feasible.

• Practical substitutions and formats

  • Carrier-free formulations: Facilitate conjugation without additional purification steps, reducing solvent use and waste; availability for this item is not specified.
  • Direct conjugates: Using pre-conjugated antibodies (HRP, AP, fluorophores) can reduce extra labeling steps and solvent consumption. Conjugation status for this item is not specified.

• Comparison snapshot (general; not item-specific)

  • Recombinant antibodies: High reproducibility, no animal bleed/ascites, scalable manufacturing.
  • Hybridoma-derived antibodies: Established clones but potential lot drift and animal use.

• Operational tips

  • Right-first-time experimentation (rigorous controls, titration) minimizes repeat runs, conserving buffers, plastics, and energy.

Pharmaceutical Uses

This product is supplied strictly for research use only and is not intended for diagnostic, therapeutic, or human/animal consumption.

• Item-specific regulatory status: Not specified for this item; refer to CoA/Spec Sheet.

• General notes (literature/general)

  • Research reagent role: Anti–Cyclin E1 antibodies are commonly used in process development, biomarker research, and analytical characterization of cell-cycle pathways, not as drug substances.
  • Formulation excipients: Antibodies used as lab reagents are often formulated with stabilizers (e.g., glycerol, sugars, proteins) and preservatives; exact composition for this item is not provided here.
  • Pharmacopoeial status: Laboratory antibodies typically do not have pharmacopeial monographs; any GMP-compatibility would require explicit documentation not provided for this product.

Physical Properties

• Item-specific (from Product Data)

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Concentration, formulation buffer, excipients, preservative: Not specified for this item; refer to CoA/Spec Sheet.

• General/literature properties for recombinant antibodies (for planning; not item specifications)

  • Physical state: Typically supplied as aqueous solution or lyophilized powder.
  • Solubility: Freely soluble in common biological buffers (PBS, TBS) and water when formulated appropriately; stability depends on pH, ionic strength, and excipients (e.g., glycerol, sugars, proteins).
  • Isoelectric point (pI): IgG pI commonly ranges ~6–9 depending on sequence/glycosylation.
  • Stability: Sensitive to repeated freeze–thaw; aggregation risk increases with thermal or mechanical stress.
  • UV characterization: Antibodies exhibit strong absorbance at 280 nm (A280) with a typical extinction coefficient around 1.3–1.6 (mg/mL)−1 for IgG; exact ε depends on sequence (not item-specific).

Quality and Grades

• Item-specific (from Product Data)

  • Grade/Purity: Recombinant, ExactAb™, Validated.

• What these designations generally imply (literature/general; not item specifications)

  • Recombinant: Produced in a defined expression system, enabling lot-to-lot consistency, reduced background from host immunoglobulins, and ethical advantages over animal-derived antibodies.
  • ExactAb™: Denotes a defined, engineered antibody format with sequence-level control and reproducible performance. Typical benefits include batch fidelity, lower off-target variability, and improved documentation. Refer to product-specific CoA for sequence/format details.
  • Validated: Performance has been assessed in one or more applications and sample types. Validation dimensions commonly include specificity to Cyclin E1, sensitivity/LOD, and species/application compatibility. Exact validated applications for this item are not specified here; consult the CoA/Spec Sheet.

• Practical quality considerations for end users

  • Documentation: Request CoA including lot number, concentration, storage buffer, preservative, and tested applications.
  • Specificity controls: Use antigen competition, knockdown/knockout lysates, or overexpression controls to confirm target recognition in your system.
  • Matrix effects: Verify background in relevant sample matrices (e.g., formalin-fixed tissue vs. cell lysates) as fixation/denaturation can alter epitope exposure.
  • Reproducibility: Recombinant production typically improves inter-lot comparability; still, record lot and dilution to ensure traceability in publications and SOPs.

Reaction and Applications

For antibodies, “applications” correspond to immunoassays and target detection rather than chemical reactions.

• Item-specific (from Product Data)

  • Manufacturer Applications: Not specified for this item; refer to CoA/Spec Sheet.

• Literature/general application landscape for anti–Cyclin E1 antibodies (not item specifications)

  • Western blot (WB): Detection of Cyclin E1 isoforms in cell and tissue lysates; recommended to include synchronized cell-cycle samples (G1/S boundary) for positive control.
  • Immunohistochemistry (IHC/IHC-P): Assessment of Cyclin E1 protein levels in fixed tissues; antigen retrieval conditions (e.g., citrate buffer pH ~6) may improve epitope exposure—optimize empirically.
  • Immunofluorescence (IF/ICC): Subcellular localization during G1/S transition; fixation/permeabilization conditions affect nuclear antigen accessibility.
  • Immunoprecipitation (IP) / Co-IP: Pull-down of Cyclin E1 and associated CDK2 complexes; include DNase/RNase as needed to disrupt nucleic acid-mediated associations.
  • ELISA: Quantitative detection in cell extracts; sandwich or indirect formats using orthogonal anti-epitope pairs.

• Experimental tips (general)

  • Specificity: Use CCNE1 knockout/siRNA cells as negative controls and overexpression constructs as positive controls.
  • Load/antigen levels: Cyclin E1 is cell-cycle regulated; enrich for G1/S via thymidine or hydroxyurea block to boost signal.
  • Denaturation: Cyclin E1 (~literature) may display epitope sensitivity to fixation; optimize retrieval and blocking to minimize background.

Reaction Conditions

Not applicable in the context of chemical reactions. Antibody performance instead depends on assay conditions.

• Item-specific tested conditions: Not specified for this item; refer to CoA/Spec Sheet.

• General assay condition guidance (literature/general)

  • WB: Denaturing SDS-PAGE, transfer to PVDF/nitrocellulose, blocking (e.g., 5% BSA/milk), primary incubation typically 1–16 h at 4–25°C; optimize dilution and wash stringency.
  • IHC/ICC: Fixation (PFA or formalin), antigen retrieval as appropriate, primary incubation 1–16 h; stringent washes reduce background.
  • IP: 1–4 h capture at 4°C with rotation; gentle washes preserve complexes; elute under denaturing or native conditions per downstream analysis. These are general guidelines and not specifications for this product.

Safety and Handling

• Item-specific hazard data

  • GHS Classification, Signal Word, H-Statements, Pictograms: Not specified for this item; refer to SDS.
  • Research Use: For research use only.

• General safety guidance for protein antibodies (literature/general)

  • PPE: Lab coat, gloves, and safety glasses recommended. Avoid inhalation of dried powders or aerosols; handle solutions to prevent splashes.
  • Hygiene: Do not eat/drink in lab; wash hands after handling. Decontaminate surfaces with appropriate detergent or 70% ethanol.
  • Incompatibilities: Avoid strong oxidizers and extremes of pH that can denature protein. Sodium hypochlorite can degrade proteins; if used for decontamination, rinse thoroughly.
  • Thermal/physical stress: Minimize freeze–thaw cycles; do not vortex aggressively to avoid aggregation and activity loss.
  • Biological origin: Recombinant production minimizes biohazard risk compared to ascites/serum-derived materials; nonetheless, treat as potentially bioactive laboratory reagent.
  • First aid (general): If contact with eyes/skin, rinse with water. If inhaled (powder/aerosol), move to fresh air. If ingested, rinse mouth with water. Seek medical advice if symptoms persist. Always consult the SDS for authoritative guidance.
  • Waste: Dispose of proteinaceous waste according to institutional and local regulations.

Solvent Selection

This product is a recombinant antibody formulated for biological use rather than chemical synthesis. Classic “solvent selection” guidance for organic reactions is not typically applicable.

• Item-specific: Formulation buffer and compatibility are not specified for this item; refer to CoA/Spec Sheet.
• General guidance (literature/general)
  • Preferred media: Physiological buffers (e.g., PBS, TBS) at neutral pH; avoid strong organic solvents that denature proteins.
  • Cosolvents: Low percentages of glycerol are commonly used to enhance freeze–thaw stability; DMSO is generally avoided for long-term storage of antibodies unless specifically validated.
  • Detergents: If required for applications (e.g., IP, WB), use mild nonionic detergents (e.g., 0.05–0.1% Tween-20) as validated for your assay.

Storage and Reconstitution

• Item-specific (from Product Data)

  • Storage conditions: Store at -20°C. Avoid repeated freezing and thawing.
  • Shipping: Shipped in an ice chest with ice pads.
  • Appearance and reconstitution instructions: Not specified for this item; refer to CoA/Spec Sheet.

• General best practices (literature/general; not item specifications)

  • Upon receipt: Inspect for container integrity and record lot/date. If liquid, briefly centrifuge to collect contents.
  • Aliquoting: Prepare single-use aliquots to prevent freeze–thaw cycles. Use low-protein-binding tubes.
  • Short-term storage: 2–8°C for days to 1–2 weeks may be acceptable for many antibodies; verify with CoA.
  • Long-term storage: -20°C or below per product guidance. If glycerol-containing, storage at -20°C (not -80°C) can prevent phase separation; if lyophilized, desiccate and store cold/dark.
  • Reconstitution (if lyophilized): Use sterile, neutral pH buffer (e.g., PBS) to the recommended concentration; allow gentle mixing without vigorous vortexing; let stand on ice to fully dissolve.
  • Stability tracking: Document freeze–thaw count, storage temperature, and working dilutions. Discard if precipitation, strong turbidity, or loss of performance is observed. Always consult the product’s CoA/Spec Sheet and SDS for definitive instructions.

Structure and Identity

Professional-grade recombinant antibody directed against human Cyclin E1. Item-specific identifiers below reflect available product data followed by general notes.

• Item-specific (from Product Data)

  • Product: Recombinant Cyclin E1 Antibody (SKU: Ab098460)
  • Grade/Purity: Recombinant, ExactAb™, Validated
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES / InChI / InChIKey / CAS / CID: Not applicable to protein biologics or not specified for this item.

• General structural features (literature/general)

  • Typical architecture: Immunoglobulin protein comprised of two heavy chains and two light chains (Ig domain folds with β-sandwich motifs), stabilized by inter- and intra-chain disulfide bonds. Recombinant format may be full-length IgG, scFv-Fc, or other engineered architecture; exact format not specified for this item.
  • Functional domains: Variable regions confer antigen recognition (paratope) against Cyclin E1 epitopes; constant regions determine isotype/effector functions (not specified here).
  • Post-translational features: Recombinant antibodies may contain defined glycosylation patterns depending on expression host; item-specific glycoform not provided.

• Descriptive 2D “structure in words” (general)

  • Y-shaped dimer of heterodimers: each arm contains a variable heavy/light domain pair forming the antigen-binding site; the stem (Fc) comprises CH2–CH3 domains. Epitope binding is to Cyclin E1, a cell-cycle regulatory protein.

Synthetic Utility

Not typically applicable. As a recombinant antibody targeting Cyclin E1, this product is not used as a building block or reagent in organic synthesis. For practical value, refer to the Reaction & Applications, Biological Roles, and Application Protocols sections that describe its use in immunoassays and protein detection.

Target Specificity

• Antigen/Target name: Cyclin E1
• Species reactivity: Not specified for this item; refer to CoA/Spec Sheet.
• Clone/format/isotype: Not specified for this item; refer to CoA/Spec Sheet.
• Epitope mapping/sequence region: Not specified for this item; refer to CoA/Spec Sheet.
• Cross-reactivity: Not specified for this item; refer to CoA/Spec Sheet.
• Conjugate/label: Not specified for this item; refer to CoA/Spec Sheet.

Only the antigen name is derived from the product title; all other parameters must be confirmed in the CoA/Spec Sheet.

Perguntas frequentes

What does ExactAb? mean?

ExactAb? indicates the product has been validated for use in rigorous antibody validation workflows. Validation may include positive/negative control samples, signal-to-noise testing, and protocol-specific QC. Lot-specific test data is published on the Certificate of Analysis where available.

How should this product be stored?

Store at ?20 °C. Avoid repeated freeze–thaw cycles. Aliquot into single-use volumes before freezing.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What does Recombinant mean?

Recombinant is a defined analytical purity tier suitable for workflows requiring a specific validated property. It specifies a minimum assay percentage, controlled limits on common impurities (water, heavy metals, residue on ignition), and lot-to-lot consistency. Recombinant is one of several purity tiers — choose based on the sensitivity and regulatory requirements of your method.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Which species reactivity has this antibody been validated against?

Validated reactivity is listed on the PDP and on each lot's datasheet. We validate against the most commonly tested species for the target (Recombinant?Cyclin E1 Antibody); cross-reactivity in untested species may exist but is not guaranteed. Contact technical support for specific species inquiries.